Oncolytics Biotech (ONCY)
NASDAQ:ONCY
Want to see ONCY full AI Analyst Report?
ONCY Stock Chart & Stats
$1.12
-$0.03(-3.70%)
At close: 4:00 PM EST
$1.12
-$0.03(-3.70%)
Day’s Range― - ―
52-Week Range$0.33 - $1.51
Previous CloseN/A
Volume216.96K
Average Volume (3M)1.46M
Market Cap
$110.71M
Enterprise Value$139.01M
Total Cash (Recent Filing)$5.49M
Total Debt (Recent Filing)$508.00K
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Jul 31, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding119,354,065
10 Day Avg. Volume1,860,387
30 Day Avg. Volume1,456,153
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-22.05
Price to Sales (P/S)0.00
P/FCF Ratio-4.17
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.23K
Enterprise Value/Ebitda-4.20
Forecast
1Y Price Target
$6.00Price Target Upside435.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Mechanism & Translational DataRobust translational and mechanistic data demonstrating innate and adaptive immune activation provide durable scientific differentiation. Biomarker‑backed evidence and observed T‑cell clonal expansion support pelareorep as a combination backbone, improving trial design, patient selection, and long‑term partnering prospects in immuno‑oncology.
Regulatory Alignment On Pivotal StudyFDA alignment on a pivotal trial design materially reduces regulatory uncertainty and clarifies endpoints and trial structure. This durable development milestone supports a credible registrational pathway, improving chances of accelerated/full approval and making future partner or payer discussions more constructive over months.
Strengthened Leadership And BoardAdding an experienced COO and a veteran biotech dealmaker to the board enhances clinical operations, development execution, and business development capabilities. These governance moves increase organizational capacity to run registrational trials, negotiate partnerships, and execute on long‑term commercialization strategies.
Bears Say
No Operating Revenue And Ongoing LossesThe company has no operating revenue and persistent multi‑year losses, creating structural reliance on external capital. Continued negative profitability constrains reinvestment capacity, forces financing needs during critical development stages, and increases dilution risk that can impair long‑term strategic optionality.
Deteriorated Balance Sheet And Negative EquityNegative shareholder equity and falling assets materially weaken the financial cushion and raise solvency risk. This structural deterioration can limit access to non‑dilutive financing, reduce bargaining leverage in partnerships, and heighten the probability of distress financing if clinical timelines slip or costs rise.
Dependence On Dilutive Financing CapacityA sizeable ATM facility signals ongoing dependence on issuing equity to fund R&D. While flexible, routine use of such facilities creates durable dilution risk, ties funding availability to market conditions, and may constrain long‑term capital structure and shareholder value if revenue or non‑dilutive partner funding do not materialize.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.33 and its highest was $1.51 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $110.71M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Jul 31, 2026 which is in 56 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on May 14, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.043 by -$0.036.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.05.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 119,354,065 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.043. Following the earnings report the stock price went down -2.523%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncolytics Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (435.71% Upside)
$6.00 (435.71% Upside)
Blogger Sentiment
Bullish
ONCY Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $15.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
153.60%
12-Months-Change
Fundamentals
Return on Equity
5132.04%
Trailing 12-Months
Asset Growth
-36.89%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY Stock 12 Month Forecast
Average Price Target
$6.00
▲(435.71% Upside)
Technical Analysis
Atossa Therapeutics
―
Oramed Pharm
―
Atara Biotherapeutics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―
Ownership Overview
Options Prices
Currently, No data available
---